All News

RheumNow Podcast square

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD

Dr, Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
RheumNow Podcast square

Rheumatology Pay Up (9.25.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
GCA.glossary.wordle

Steroid Delusions in Giant Cell Arteritis

Jack Cush, MD

A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.

Read Article
RheumNow Podcast square

Early RA Referral Clinics Work (9.18.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
RheumNow Podcast square

A Day of Infamy (9.11.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz!

Read Article
RA.Xray.Hands

JAMA: Review of Adult Rheumatoid Arthritis

Jack Cush, MD

Smolen, Kerschbaumer, Aletaha, and Robinson have published a comprehensive review article of rheumatoid arthritis (RA) in JAMA, noting significant changes to our understanding and treatment guidelines.

Read Article
RheumNow Podcast square

Treating Obesity is Disease-Modifying (9.4.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!

Read Article
DERM on RheumNow PODCAST (September 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. https://t.co/QYX9G5UFg5
Dr. John Cush RheumNow ( View Tweet)
52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA https://t.co/Vhx717rw5T https://t.co/OBMdjsegIq

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved baricitinib (Olumiant) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata https://t.co/OTXXQvNruw https://t.co/xrg5ocWyjo

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center, DBRPCT of tofacitinib 11 mg/d vs PBO in 100 knee OA pts (KL Gr 1-2); At wk 12 there was NO significant differences betw groups in VAS Pain, or other outcomes-WOMAC, Oxford Knee Score, EQ-5D-5L, analgesic use https://t.co/VDtgY7hTm4 https://t.co/PveouQbI8r

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: The TriNetX retrospective study found that JAK inhibitors significantly increased VTE risk in rheumatoid arthritis patients undergoing hip or knee replacement compared to TNF inhibitors. Check your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.

Links:

Dr. John Cush RheumNow ( View Tweet)

Research at Cedars-Sinai used synthetic noncoding RNA TY1 in a bleomycin mouse model of scleroderma, noting improved exercise tolerance, CV function, lung hydroxyproline, skin thickness, less fibrosis. TY1 attenuates the cGAS/STING pathway https://t.co/jOwlPokxKE https://t.co/aIgIPzZbGa

Links:

Dr. John Cush RheumNow ( View Tweet)
OL study of tofacitinib in 20 juvenile DM pts w/ calcinosis cutis (11 boys; age 10.4 yrs; CC x 31 mos). Calcinosis assessed by CT scan showed decr Agatston score from 6,349 to 4,007. No SAE. https://t.co/UDLLwce3mp https://t.co/BflewkO0RM

Links:

Dr. John Cush RheumNow ( View Tweet)
TriNetX retrospective EHR study showed VTE in #RA not incr by taking JAKi. Pts undergoing THA/TKA Rx w/ JAKi (n 284) vs TNFi (n 288). VTE- 17 JAKi (6%) vs 11 TNFi (3.8%)- nonsignif incr (RR 1.57) https://t.co/OM5ipieQtr https://t.co/ng8b9EkWmT

Links:

Dr. John Cush RheumNow ( View Tweet)
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG https://t.co/Dn5DgeaX7N

Links:

Dr. John Cush RheumNow ( View Tweet)
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG https://t.co/N9rg30EA4W

Links:

Dr. John Cush RheumNow ( View Tweet)
High BMI decreases the odds for MDA in PsA, esp w/ TNFi Rx (but not Inflx, IL-17i, IL-12/23i, IL-23i, JAKi). Longitudinal PsA cohort 1291 pts (mean BMI 29); Higher BMI independently assoc w/ signif. lower odds for MDA (OR 0.97), also female, age, smoking, FM & Xray damage. https://t.co/zAJ8Pmk1HY
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Brepocitinib to Treat Dermatomyositis The FDA and Priovant recently announced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM. https://t.co/blsl1365XS
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×